Technical Analysis for TIL - Instil Bio, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 20 DMA | Bullish | -8.49% | |
| Pocket Pivot | Bullish Swing Setup | -8.49% | |
| Wide Bands | Range Expansion | -8.49% | |
| 20 DMA Resistance | Bearish | -2.99% | |
| Wide Bands | Range Expansion | -2.99% | |
| 20 DMA Resistance | Bearish | -5.77% | |
| Shooting Star Candlestick | Bearish | -5.77% | |
| Lizard Bearish | Bearish Day Trade Setup | -5.77% | |
| Multiple of Ten Bearish | Other | -5.77% | |
| Wide Bands | Range Expansion | -5.77% |
| Alert | Time |
|---|---|
| Down 10% | about 4 hours ago |
| Fell Below Previous Day's Low | about 4 hours ago |
| Fell Below 10 DMA | about 4 hours ago |
| 10 DMA Support | about 6 hours ago |
| Down 5% | about 6 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/11/2024
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 (FOLR1) with indications, including gynecological, non-small cell lung cancer, and others. The company was incorporated in 2018 and is based in Dallas, Texas.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Oncology Cancer Immunotherapy Cell Therapy Non Small Cell Lung Cancer Melanoma Lymphocytes Cervical Cancer Head And Neck Squamous Cell Carcinoma Tumor Infiltrating Lymphocytes Cutaneous Squamous Cell Carcinoma Therapies For The Treatment Of Patients With Cancer
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Oncology Cancer Immunotherapy Cell Therapy Non Small Cell Lung Cancer Melanoma Lymphocytes Cervical Cancer Head And Neck Squamous Cell Carcinoma Tumor Infiltrating Lymphocytes Cutaneous Squamous Cell Carcinoma Therapies For The Treatment Of Patients With Cancer
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 92.0 |
| 52 Week Low | 6.07 |
| Average Volume | 149,531 |
| 200-Day Moving Average | 20.29 |
| 50-Day Moving Average | 36.44 |
| 20-Day Moving Average | 27.74 |
| 10-Day Moving Average | 26.53 |
| Average True Range | 3.68 |
| RSI (14) | 47.92 |
| ADX | 10.41 |
| +DI | 22.85 |
| -DI | 21.02 |
| Chandelier Exit (Long, 3 ATRs) | 26.19 |
| Chandelier Exit (Short, 3 ATRs) | 33.57 |
| Upper Bollinger Bands | 33.38 |
| Lower Bollinger Band | 22.11 |
| Percent B (%b) | 0.56 |
| BandWidth | 40.65 |
| MACD Line | -1.89 |
| MACD Signal Line | -2.52 |
| MACD Histogram | 0.638 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 32.89 | ||||
| Resistance 3 (R3) | 32.72 | 31.06 | 32.14 | ||
| Resistance 2 (R2) | 31.06 | 29.92 | 31.14 | 31.89 | |
| Resistance 1 (R1) | 29.73 | 29.21 | 30.40 | 29.90 | 31.64 |
| Pivot Point | 28.07 | 28.07 | 28.40 | 28.15 | 28.07 |
| Support 1 (S1) | 26.74 | 26.93 | 27.41 | 26.91 | 25.16 |
| Support 2 (S2) | 25.08 | 26.22 | 25.16 | 24.91 | |
| Support 3 (S3) | 23.75 | 25.08 | 24.66 | ||
| Support 4 (S4) | 23.92 |
